News

Preliminary analysis showed that MLN1202 was well tolerated and fully met its primary endpoint of a significant reduction in C-Reactive Protein (CRP) levels, an inflammatory biomarker associated with

The drug is deigned to improve chronic inflammation in patients with CIAS1-Associated Periodic Syndromes (CAPS), a spectrum of rare genetic disorders. Fast track designation are designed to aid

Picoplatin is a new generation platinum therapy that provides a differentiated spectrum of activity and an improved safety profile. The drug is designed to overcome platinum resistance associated

The trial, performed in collaboration with a team based in Leicester, UK, will oversee the vaccination of 560 healthy adult individuals. Conventional vaccines against H5 and H9 avian

The company voluntarily suspended the trial on March 14th 2006 after three serious cases of pericardial effusion – a condition characterized by an accumulation of fluid around the

Humaneering is KaloBios’s proprietary method for converting non-human antibodies into engineered human antibodies for therapeutic drug applications. The system has the advantage of maintaining epitope specificity and increasing

The company announced its intentions regarding the development of the drug following the recent completion of a pre-IND meeting with the FDA. Inspire expects to submit the IND

“This financing brings us a long way toward meeting our funding goals and putting us in position to go forward with our phase II trials upon receipt of

VaxGen announced in May 2005 that it would fund proof-of-concept studies and then determine whether to pursue commercial development of the vaccine candidate. The initial proof-of-concept phase was